tobramycin inhalation / Generic mfg. - LARVOL DELTA

A Silent Complication: Rare Case of Inhaled Tobramycin Associated Ototoxicity in Patient With Preserved Renal Function (ATS 2026) - No abstract available

Clinical • Bronchiectasis • Cough • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Application of inhaled tobramycin in the treatment of severe pneumonia patients with mechanical ventilation: a randomized, double-blind, parallel controlled, exploratory study (ChiCTR) - P4 | N=104 | Not yet recruiting | Sponsor: The Affiliated Hospital of Medical College Qingdao University, China; The Affiliated Hospital of Medical College Qingdao University, China

New P4 trial • Infectious Disease • Pneumonia • Respiratory Diseases

Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study. (PubMed, ERJ Open Res) - "Using molecular methods, we analysed changes in the sputum microbiota in samples from 107 participants with bronchiectasis recruited to the iBEST-1 study, and defined community endotypes based on response to tobramycin inhalation powder (TIP) treatment...qPCR may be a useful, culture-independent microbiological efficacy end-point in clinical trials. Using qPCR, participants with bronchiectasis were stratified into endotpyes which predicted response to antimicrobial treatment, potentially allowing for a more personalised approach to therapy."

Journal • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Inhaled Tobramycin Dose and Systemic Absorption in Lung Transplant Recipients Without Cystic Fibrosis. (PubMed, Transpl Infect Dis) - "LTRs without CF commonly had systemic tobramycin exposure during inhaled therapy. The 300 mg dose was linked to higher serum concentrations, supporting reduced dosing and active serum concentration monitoring to enhance safety."

Journal • Acute Kidney Injury • Cystic Fibrosis • Genetic Disorders • Immunology • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Transplantation

The Effect of Inhaled Tobramycin Use in Neonatal and Pediatric Intensive Care Unit Populations (ASHP 2025) - No abstract available

Clinical • Critical care • Pediatrics

Evaluation of Inhaled Tobramycin Use in the Neonatal Intensive Care Unit (ASHP 2025) - No abstract available

Critical care

Inhaled Tobramycin Systemic Absorption in Lung Transplant Recipients without Cystic Fibrosis (ASHP 2025) - No abstract available

Clinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases • Transplantation

Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach. (PubMed, J Adv Res) - "This tobramycin spongy-like dry powder, identified as high lectin affinity and excellent respiratory variability tolerance, holds significant promise for the treatment of pulmonary infections."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Recurrent Lung Infections In A kidney Transplant Patient: A Diagnostic Clue Reveals CD19 Deficiency. (ACAAI 2025) - "Her immunosuppressive regimen included mycophenolate, tacrolimus, and prednisone, with recent addition of inhaled tobramycin. Discussion In kidney transplant recipients with recurrent infections, persistent CD19+ B cell deficiency—even in the presence of normal immunoglobulin levels—should prompt consideration of functional antibody defects. Early recognition by pre & post transplant Immunoglobulin levels and CD19 counts are key to optimizing outcomes in this vulnerable population."

Clinical • Immunology • Infectious Disease • Nephrology • Pneumococcal Infections • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • Solid Organ Transplantation • Transplantation • CD4 • CD8

An Unusual Overlap: Coexisting Cystic Fibrosis and Common Variable Immunodeficiency-like Phenotype in an Adult Patient (ACAAI 2025) - "Despite being on an optimized CF regimen, including Trikafta, Pulmozyme, albuterol, olodaterol, and inhaled tobramycin, he experienced over 90 CF exacerbations. In patients with CF who continue to experience frequent exacerbations despite optimal management, further immunologic evaluation should be considered. Early identification and initiation of therapy may lead to improved outcomes"

Clinical • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency • Psychiatry • Pulmonary Disease • Respiratory Diseases • CD4

GRANULOMATOUS RESTRICTIVE LUNG DISEASE IN T-CELL ACTIVATION DYSFUNCTION AND HYPOGAMMAGLOBULINEMIA (CHEST 2025) - "The obstructive component of his lung disease was treated with a mometasone-formoterol combination inhaler, montelukast, cetirizine and Dupilumab, an IL-4 and IL-13 pathway inhibitor...In addition, he receives monthly IVIG infusions and bi-monthly inhaled tobramycin...GLILD treatment strategies typically include immunosuppressive agents such as glucocorticoids, rituximab, azathioprine, and mycophenolate mofetil [2]... The necrotizing nature of our patient's granulomas suggests a unique immune dysregulation mechanism, potentially involving defective granuloma resolution and chronic inflammation-driven airway remodeling. Given the absence of a confirmed genetic etiology, further molecular research is warranted to better understand the underlying immune dysfunction."

Asthma • Bronchiectasis • CNS Disorders • Endocrine Disorders • Epilepsy • Hypoparathyroidism • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Tuberculosis • Vasculitis • HAVCR2 • IFNG • IL13 • IL4

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution (The Manila Times) - "The Ritedose formulation is preservative-free and packaged as 300 mg doses in 5 ml ampules, to be administered through a nebulizer device. The medication is now available for purchase."

ANDA • Generic launch • Cystic Fibrosis • Infectious Disease

ENDOBRONCHIAL ASPERGILLOMA IN A LUNG TRANSPLANT PATIENT (CHEST 2025) - "He was started on posaconazole for treatment of invasive endobronchial aspergillosis. Antifungal prophylaxis with inhaled tobramycin and azole therapy remains key in protecting lung transplant patients against invasive infections. In this case, undertreatment of prior aspergillosis infection only treated with inhaled amphotericin likely increased his risk for inadequate treatment."

Clinical • Cardiovascular • Fibrosis • Infectious Disease • Interstitial Lung Disease • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Transplantation

Mucus-penetrating archaeolipid nanocarriers delivering Thymus vulgaris essential oil and tobramycin: A multifunctional approach against Pseudomonas aeruginosa biofilms and inflammation. (PubMed, Eur J Pharm Biopharm) - "Inhaled tobramycin (TB) is the standard antibiotic therapy but has limited efficacy due to poor biofilm penetration and bacterial tolerance, while Thymus vulgaris essential oil (EOT) provides antioxidant and anti-inflammatory effects but is hindered by low solubility and instability. Moreover, NAL-EOT/TB lowered ROS in neutrophil-like cells and achieved greater IL-8 reduction than dexamethasone. These findings support NAL-EOT/TB as a multifunctional nanotherapeutic platform to address mucus penetration, biofilm disruption, and airway inflammation in CF."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CXCL8

A CAVITY WITHOUT CULTURE: CYTOPATHOLOGIC DIAGNOSIS OF ACTINOMYCES INFECTION (CHEST 2025) - "IV therapy directed at both pseudomonas and actinomyces was initiated with transition to 4 weeks of amoxicillin with outpatient follow-up...He has been maintained on alternating-month inhaled tobramycin and percussive therapy with continued low-grade hemoptysis but without recent bronchiectasis exacerbation requiring hospitalization... Actinomycosis is a rare infection caused by anerobic bacteria, which is commonly the result of aspiration. The imaging findings of actinomycosis are varied and therefore can present a diagnostic challenge. Careful review of nonmicrobiologic testing, such as cytopathology, may also reveal potential etiologies and lead to acceleration of appropriate workup and management to avoid further morbidity."

Bronchiectasis • Dental Disorders • Diabetes • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases

CONVERSION OF CFTR-RELATED METABOLIC SYNDROME TO CYSTIC FIBROSIS BASED ON CLINICAL FEATURES (CHEST 2025) - "She completed eradication therapy with inhaled tobramycin and ciprofloxacin and subsequently started inhaled steroids, hypertonic saline, and chest physiotherapy. This case highlights the need for close monitoring of cystic fibrosis gene carriers during childhood. Despite initial screenings that place these individuals under the CRMS/CFSPID category, there remains a potential for these patients to have significant morbidity with high risk of affecting long-term health outcomes. By identifying emerging CF-related symptoms early, healthcare providers can better support these patients' health trajectories, leading to improved prognoses and quality of life."

Clinical • Bronchiectasis • Chronic Cough • Cough • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Metabolic Disorders • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sinusitis • CFTR

Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis (WBC 2025) - "Inhaled tobramycin significantly alleviates respiratory symptoms in patients with bronchiectasis and P. aeruginosa infection, particularly in those with high baseline bacterial load. Improvements in cough, sputum, congestion, breathlessness and chest pain support its role as an effective symptom-targeted therapy for this population."

Clinical • Bronchiectasis • Cough • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis (WBC 2025) - "We did a post-hoc analysis to determine the changes in BECs upon inhaled tobramycin and evaluated the therapeutic outcomes stratified by BECs levels... Higher BECs are associated with P. aeruginosa infection in bronchiectasis, correlating with more severe disease. Inhaled antibiotics may increase BECs and ameliorate symptoms, irrespective of baseline BECs levels."

Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Psychometric validation and determination of the minimal clinically important difference for the bronchiectasis health questionnaire in adults with bronchiectasis (WBC 2024) - "Methods We enrolled a cross-sectional observational cohort of 436 bronchiectasis patients and another cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection in a randomized trial...The MCID for BHQ was consistently identified as 3 points. Conclusions The BHQ represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes."

Clinical • Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of inhaled tobramycin (Vantobra) in adult patients with bronchiectasis and P. aeruginosa in sputum: a prospective observational study (WBC 2024) - "Our findings indicate that Vantobra may be effective in eradicating PA and improving quality of life of bronchiectasis patients with a good safety profile."

Clinical • Observational data • Bronchiectasis • Infectious Disease • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Killing two birds with one stone: emergence of colistin and cefiderocol resistance in a mucoid MDR Acinetobacter baumannii under colistin pressure. (PubMed, Front Microbiol) - "Due to Pseudomonas aeruginosa infection, she received inhaled tobramycin and COL treatment. Considering that lung transplantation still represents a life-saving option for CF patient with advanced lung disease, this study highlights the critical need for careful administration of last-resort molecules in patients that may face immunosuppression. Indeed, given the possibility of simultaneous emergence of resistance and the limited treatment options available to patients infected with MDR A. baumannii, last-resort antibiotics should be spared to avoid selection of pan-resistant microorganisms."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

Changes in Medicaid claims for chronic medications for cystic fibrosis (NACFC 2025) - "Background: Several published reports have described changes in chronic medications for cystic fibrosis (CF) after the initiation of elexacaftortezacaftor-ivacaftor (ETI)...Prescriptions for inhaled tobramycin were difficult to differentiate from prescriptions for IV tobramycin, so we have not yet included tobramycin in our analysis... Prescriptions for dornase alfa and inhaled aztreonam decreased after the introduction of ETI, but to a greater extent than recorded in the CFFPR (approximately 15% and 25%, respectively). These results support the use of claims data to complement CFFPR analyses and prospective studies to understand changes in chronic CF medications use after ETI. Our analysis is limited by the inability to examine only people with CF, to determine if people with CF took the medications that were prescribed, or whether changes in medications occurred via shared decision-making with the CF care team."

Medicaid • Reimbursement • US reimbursement • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Azithromycin use in the UK and US and its effect on ppFEV1: A target trial emulation approach (NACFC 2025) - "Following the RCT eligibility criteria we restricted our analysis to PwCF aged 6–21, with baseline ppFEV1 ≥40%, and excluded users of AZ in the previous year, as well as users of dornase alfa, tobramycin, and inhaled steroids in the previous three months. Conclusions based on the trial emulations using UK and US registry data align with the conclusions reported in the published target trial. Target trial emulation is a promising framework for utilizing observational data found in registries and longitudinal cohorts to provide evidence, under certain assumptions, that may supplement evidence from RCTs. We show the utility of this method in CF registry data in the UK and the US."

Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

The role of Advanced Practice Providers (APPs) in the CF care community (NACFC 2025) - "Table 1 (abstract 390): Number of Medicaid prescription fills by year Percent change from 2018 to 2022 2018 2019 2020 2021 2022 Inhaled dornase alfa 70,330 69,972 68,351 63,994 59,251 -16% Inhaled aztreonam 5,716 5,947 5,230 4,425 3,792 -34% Inhaled tobramycin 11,420 11,523 10,351 9,904 8,890 -22% Pancreatic enzyme replacement therapy (PERT) 249,202 274,158 280,890 288,053 287,319 +15% Tezacaftor/ivacaftor 6,208 12,281 5,040 3,229 731 -88% elexacaftor/tezacaftor/ivacaftor (ETI) NA 2,245 34,631 46,943 56,184 +2,402% (2019 to 2022) A total of 103 responses were received. APPs serve a vital role of the clinical and non-clinical operations of CF care teams, but we lack understanding of the full scope of the work they encompass. A survey of the APP workforce demonstrated utilization in both inpatient and outpatient clinical environments and near-equal distribution across the lifespan. The survey also demonstrated that many APPs are working in non-clinical capacities,..."

Metastases • Cystic Fibrosis • Genetic Disorders • Immunology • Pediatrics • Respiratory Diseases